Ricardo Ferreira is currently a PhD student in pharmacy at Faculty of Pharmacy of the University of Lisbon (FFUL). In 2019, he concluded his degree in Biochemistry at the University of Évora (2016-2019). In the last year of his bachelor, RF carried out a 6-month internship under the supervision of Professor Elsa Lamy, focused on evaluating the influence of food, especially red wine, on the salivary protein composition. During that period he was involved on the collection of samples, in sample processing by centrifugation, protein quantification by Bradford assay, and SDS-PAGE gel running and evaluation. Later in 2019, he moved to Lisbon to start the master in Medicinal and Pharmaceutical Chemistry at FFUL. In his master thesis, RF developed novel p53 activators for anticancer therapy at the Medicinal Organic Chemistry group (FFUL) under the supervision of Professors Maria M. M. Santos and Ana Paula Francisco. During this period, he synthesized and performed stability studies (PBS and plasma) of novel spiropyrazoline onxindoles and hybrid compounds. The dissertation allowed him to acquire experience and deepen knowledge in the area of medicinal chemistry and organic chemistry. This work led to a clasification of 19 values of the master's thesis and to 2 poster communications in scientific meetings. Since January to September 2022, RF was a BI holder of the project "Targeting mutant p53 with tryptophanol-derived small molecules" (PTDC/QUI-QOR/1304/2020), at the Research Institute for Medicines (iMed.ULisboa), at Faculty of Pharmacy of the University of Lisbon (FFUL) and he was involved in the development of tryptophanol-derived compounds and he had his first contact with computational chemistry. During that time RF presented 3 poster communications at scientific meetings. RF also travelled to Szeged in May 2022 to separate enantiomers by HPLC, being part of the project Bilateral action FCT/NKFIH 2019/2020. In October 2022, RF started his PhD in pharmacy at FFUL, under supervision of Professor Maria M. M. Santos (FFUL) and Professor Mattia Mori (USiena). RF is currently working in development of mutant p53 activators. His project is entitled "Targeting R280K and R273H mutants p53 with tryptophanol-derived small molecules" (2022.11539.BD) and consists in a multidisciplinary project with different tasks of computational chesmitry, synthesis and biochemical assays. Since the begining of his PhD, RF already presented several poster communications, 1 flash poster presentation and 2 oral communications in science meetings.